Kolon Life Science acquire approval of tumor killing virus therapy

Published: 2018-06-20 16:32:57

Updated: 2018-06-20 16:32:57

Kolon Life Science(CEO Woo-Seok Lee) announced on the 15^th that the company acquired a patent of the poxvirus promoter,’ the company’s next pipeline that increases efficacy of the oncolytic virus treatment(also known as KLS-3020) after Invossa.

According to the company, KLS-3020, a tumor killing therapy, is designed to selectively kill targeted cancer cells without damaging normal cells. It is...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.